Skip to main content

Table 4 Baseline levels of the measured markers according to clinical endpoint or no endpoint

From: vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

 

Endpoint (n = 73)

No endpoint (n = 927)

P-value§

vWF, %

113 (93, 141)

105 (81, 133)

0.032

ADAMTS-13 antigen, ng/mL

506 (452, 576)

533 (462, 607)

0.147

ADAMTS-13 activity, IU/mL

1.00 (0.73, 1.13)

1.03 (0.83, 1.19)

0.212

Ratio antigen

0.23 (0.17, 0.29)

0.20 (0.15, 0.26)

0.012

Ratio activity

119 (88, 175)

107 (77, 150)

0.051

Platelet count (× 109/L)

221 (181, 272)

228 (196, 263)

0.446

  1. Values are given as median (25th, 75th percentiles)
  2. § p-values refer to differences between the groups with high or low RPR
  3. Significant p-values are highlighted with boldface